Al Sobhi Enaam, Zahrani Zayed, Zevallos Eduardo, Zuraiki Abdo
Department of Pathology and Laboratory Medicine, King Khalid National Guard Hospital, Jeddah, Saudi Arabia.
Hematology. 2007 Feb;12(1):49-53. doi: 10.1080/10245330600937929.
Imatinib is one of the most recent medications used for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). It is an orally administered protein-tyrosine kinase inhibitor, an enzyme which is produced by BCR-ABL fusion which results from translocation of 9:22 chromosome (Philadelphia chromosome). Imatinib blocks proliferation and induces apoptosis of BCR-ABL-expression in CML. Many side effects produced by imatinib have been documented but its induction of hepatotoxcity has been rarely reported. Only a few cases so far have been reported in the literature and almost all were in females. We describe another case of hepatotoxicity due to imatinib in a 17-year old female with clinical, laboratory and histopathological changes. The case described here suggests that imatinib may also induce immune hepatitis, in some patients.
伊马替尼是治疗慢性粒细胞白血病（CML）和胃肠道间质瘤（GIST）的最新药物之一。它是一种口服的蛋白酪氨酸激酶抑制剂，该酶由9号和22号染色体易位（费城染色体）产生的BCR-ABL融合基因所产生。伊马替尼可阻断CML中BCR-ABL表达的增殖并诱导其凋亡。伊马替尼产生的许多副作用已有文献记载，但其诱导肝毒性的情况鲜有报道。迄今为止，文献中仅报道了少数病例，几乎所有病例均为女性。我们描述了另一例17岁女性因伊马替尼导致肝毒性的病例，伴有临床、实验室和组织病理学改变。此处描述的病例表明，在某些患者中，伊马替尼也可能诱发免疫性肝炎。
